Scarica l'app Stockscreener
0.99
11.56%
0.1026
Dopo l'orario di chiusura:
.99
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Verrica Prices of $42 Million Public Offering - citybiz
VRCAVerrica Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Verrica Announces Pricing of $42.0 Million Public Offering - GlobeNewswire
Verrica Pharmaceuticals Raises $42M Through Public Offering of Shares and Warrants | VRCA Stock News - StockTitan
Form 424B5 Verrica Pharmaceuticals - StreetInsider.com
Verrica Pharmaceuticals announces proposed public offering - MSN
Verrica Announces Proposed Public Offering - The Manila Times
Verrica Pharmaceuticals Announces Public Offering of Stock and Warrants with Jefferies | VRCA Stock News - StockTitan
Verrica Pharmaceuticals Reports Q3 2024 Financials and Restructuring Plans - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock - Investing.com
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock By Investing.com - Investing.com UK
Q1 Earnings Forecast for VRCA Issued By HC Wainwright - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to “Neutral” at HC Wainwright - Defense World
Verrica downgraded to sector perform by RBC Capital - MSN
Verrica Pharmaceuticals’ (VRCA) Hold Rating Reaffirmed at Needham & Company LLC - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
Verrica Pharmaceuticals Announces Leadership Transition and Financial Results for Q3 2024 - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to "Neutral" at HC Wainwright - MarketBeat
RBC Capital Downgrades Verrica Pharmaceuticals (VRCA) - MSN
Verrica Pharmaceuticals Reports Q3 2024 EPS of -$0.49 and Revenue of -$1.9 Million, Misses Estimates - GuruFocus.com
Verrica Pharmaceuticals stock hits 52-week low at $0.93 - Investing.com
U.S. Stock market: Bluejay Diagnostics (+105.33%), Zoomcar Holdings (+180.40%), and Verrica Pharmaceuticals(+39.10%) among the most volatile stocks during mid day trading - Business Upturn
Verrica Pharmaceuticals stock hits 52-week low at $0.93 By Investing.com - Investing.com South Africa
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Sector Perform Rating by Royal Bank of Canada - MarketBeat
Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO - Marketscreener.com
Verrica Pharmaceuticals earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Shares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational Changes - MarketWatch
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership - The Bakersfield Californian
Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring - TipRanks
Botanix Pharmaceuticals Poised for Market Impact with Sofdra Launch - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Expands By 24.8% - MarketBeat
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - GlobeNewswire
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection - Law360
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Given New $10.00 Price Target at TD Cowen - MarketBeat
Verrica shares price target cut by TD Cowen - Investing.com Canada
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc.VRCA - Business Wire
GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Verrica Pharmaceuticals reports board changes, non-compliance - Investing.com India
Verrica Pharmaceuticals reports board changes, non-compliance By Investing.com - Investing.com Australia
Recent Insider Activity Could Benefit Verrica Pharmaceuticals Inc (VRCA) - Knox Daily
Verrica Pharmaceuticals Strives for Nasdaq Compliance - TipRanks
Optinose Names Terry Kohler as CFO - MarketWatch
Optinose names Terry Kohler as new CFO By Investing.com - Investing.com UK
Optinose Appoints Terry Kohler as Chief Financial Officer - Marketscreener.com
The Significance of Moving Averages in Verrica Pharmaceuticals Inc Inc. (VRCA) Price Performance - The InvestChronicle
Verrica Pharmaceuticals Inc (VRCA)’s stock price range in the last year - US Post News
Financial Fitness Check: Examining Verrica Pharmaceuticals Inc (VRCA)’s Key Ratios - The Dwinnex
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):